E-DRUG: Urge Johns Hopkins Univ to Accelerate TB Innovation & Keep it Accessible For All
----------------------------------------------------------------------------------------
ACTION ALERT
Dear colleagues,
Take Action for TB Today!
Sign and share this petition now:
https://uaem.wufoo.com/forms/z1dxtbgq0ieib3a/
Please join the Universities Allied for Essential Medicines (UAEM) and
other organizations, including the Access Campaign of Doctors Without
Borders\Médecins Sans Frontières (MSF), Treatment Action Group (TAG), The
Global TB Community Advisory Board (TB CAB) and Public Citizen, in urging
Johns Hopkins University (JHU) to commit to a global public health
approach in the licensing of sutezolid, a potentially important drug for
the treatment of tuberculosis (TB) that was developed at the University.
JHU is currently in discussions with a private company called Sequella
about exclusively licensing patents for this potentially life-saving drug.
Petitioners are seeking accountability and transparency throughout the
process and ask JHU to make the terms and conditions of the licensing
agreement available for review both before and after it is finalized. A
licensing agreement that does not include necessary provisions to ensure
timely development, affordability and accessibility of this medicine could
have detrimental effects on the lives of TB patients globally.
Sutezolid is an antimycobacterial agent, developed at JHU, that has been
shown to have promising activity against both drug-susceptible and
drug-resistant tuberculosis (DR-TB). Early studies indicate that addition
of sutezolid to the standard TB treatment regimen leads to significantly
improved efficacy. Sutezolid could represent a turning point in managing
this global public health crisis.
Sign the petition now to urge Johns Hopkins University to accelerate
important TB innovation and ensure it's accessible for all:
https://uaem.wufoo.com/forms/z1dxtbgq0ieib3a/
Thanks and best regards,
Michelle
Michelle French
Sr. Communications Manager, MSF Access Campaign
michelle.french@newyork.msf.org